Patrys Announces Favorable Results in Early Trials with PAT-SM6 for Multiple Myeloma

Early results of a phase-1/-2a indicate that an infused monoclonal antibody treatment may target the abnormal cells associated with multiple myeloma while stimulating an immune response.

A biotechnology company, Patrys, recently announced the results of an early phase-1/-2a open-label trial in patients with relapsed or refractory multiple myeloma (MM).

The small trial included 10 males and 2 females with a median age of 71 years among all participants. Patients received infusions of the company's investigational monoclonal antibody treatment, codenamed PAT-SM6, at 4 different doses ranging from 0.3 to 6 mg/kg.

Patients receiving PAT-SM6 did not experience any serious adverse events, and one-third of patients showed signs of stable disease. Researchers also confirmed that PAT-SM6 specifically targets abnormal cells associated with multiple myeloma while stimulating the patient's immune system, increasing CD8+, natural killer, and regulatory T-cells.

Although the medication has been tested as monotherapy, scientists at Patrys believe the medication may work synergistically with proteasome inhibitors. According to researchers, the next phase of investigation will involve combination therapy with Amgen’s carfilzomib.

In a press release, CEO Marie Roskow stated, “The trial results are especially exciting because they reflect single-agent activity in a difficult-to-treat population."